Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Journal of Integrative and Complementary Medicine · 2026-01 · 32 (1) · 40-46
DOI: 10.1177/27683605251379004 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Integrative and Complementary Medicine, online erschienen am 23.01.2026. Verfasst von Wenli Shang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, China. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Drug Treatment, Curcumin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Key Research and Development Projects of Shaanxi Province.
Abstract (Originalsprache)
Background
The Coronavirus disease-2019 (COVID-19) pandemic continues, and the death toll continues to surge. This systematic review and meta-analysis aimed to determine the efficacy of nanocurcumin on mortality in patients with COVID-19.
Methods
A systematic search was performed in PubMed, Embase, Cochrane Library, and clinicaltrials.gov up to November 2024, without language restrictions. Inclusion criteria: (1) inclusion of hospitalized patients with COVID-19 who are 18 years or older; (2) polymerase chain reaction positive for severe acute respiratory syndrome coronavirus-2; and (3) use of a randomized controlled design to make a comparison of nanocurcumin with placebo. The Cochrane risk-of-bias tool for randomized trials was used to assess the risk of bias. Studies were pooled to risk ratios (RRs) and standardized mean differences (SMDs), with 95% confidence intervals (CIs).
Results
Six trials (enrolling 333 participants) met the inclusion criteria. Nanocurcumin therapy showed significant improvements on mortality (RR 0.47, 95% CI 0.25–0.88; p = 0.02), interleukin-6 (IL-6) (SMD −0.30, 95% CI −0.56 to −0.04; p = 0.02), tumor necrosis factor-α (TNF-α) (SMD −0.63, 95% CI −1.16 to −0.10; p = 0.02), and IL-1β (SMD −0.88, 95% CI −1.37 to −0.39; p = 0.0004).
Conclusions
Nanocurcumin significantly reduced mortality, IL-6, TNF-α, and IL-1β in hospitalized patients with COVID-19. Given the lack of safety data and concerns about the risk of bias, the use of nanocurcumin in COVID-19 requires further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shaanxi Provincial People's Hospital, Xi'an, China.
ORCID-Profile: Dong Han
Förderung
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Shang, W., Wang, G., & Han, D. (2026). Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Integrative and Complementary Medicine, 32(1), 40-46. https://doi.org/10.1177/27683605251379004
Vancouver
Shang W, Wang G, Han D. Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Integrative and Complementary Medicine. 2026;32(1):40-46. doi:10.1177/27683605251379004
BibTeX
@article{Shang2026,
author = {Shang, Wenli and Wang, Guizuo and Han, Dong},
title = {Benefits of Nanocurcumin on Mortality in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of Integrative and Complementary Medicine},
year = {2026},
volume = {32},
number = {1},
pages = {40--46},
doi = {10.1177/27683605251379004}
}
EUVIMED